| SC 13G/A | 2024-02-09 | FMR LLC | BioXcel Therapeutics, Inc. | 2,518,564 | 8.6% | EDGAR |
| SC 13G/A | 2024-02-07 | ADAGE CAPITAL PARTNERS GP, L.L.C. | BioXcel Therapeutics, Inc. | 465,381 | 1.6% | EDGAR |
| SC 13G/A | 2023-10-19 | BioXcel Holdings, Inc. | BioXcel Therapeutics, Inc. | 8,901,750 | 30.1% | EDGAR |
| SC 13G/A | 2023-10-13 | FMR LLC | BioXcel Therapeutics, Inc. | 2,700,727 | 9.2% | EDGAR |
| SC 13D | 2023-09-28 | BioXcel LLC | BioXcel Therapeutics, Inc. | 8,546,750 | 29.2% | EDGAR |
| SC 13G/A | 2023-04-04 | BioXcel Holdings, Inc. | BioXcel Therapeutics, Inc. | 8,546,750 | 29.5% | EDGAR |
| SC 13G/A | 2023-02-14 | BioXcel Holdings, Inc. | BioXcel Therapeutics, Inc. | 8,546,750 | 30.5% | EDGAR |
| SC 13G/A | 2023-02-14 | ALLIANCEBERNSTEIN L.P. | BioXcel Therapeutics, Inc. | 24,000 | 0.1% | EDGAR |
| SC 13G/A | 2023-02-09 | FMR LLC | BioXcel Therapeutics, Inc. | 4,203,436 | 15.0% | EDGAR |
| SC 13G/A | 2023-02-09 | BlackRock Inc. | BioXcel Therapeutics, Inc. | 1,312,403 | 4.7% | EDGAR |
| SC 13G | 2023-02-03 | BlackRock Inc. | BioXcel Therapeutics, Inc. | 1,462,922 | 5.2% | EDGAR |
| SC 13G | 2023-02-02 | ADAGE CAPITAL PARTNERS GP, L.L.C. | BioXcel Therapeutics, Inc. | 1,548,591 | 5.5% | EDGAR |
| SC 13G/A | 2022-02-14 | BioXcel Holdings, Inc. | BioXcel Therapeutics, Inc. | 8,546,750 | 30.5% | EDGAR |
| SC 13G | 2022-02-14 | ALLIANCEBERNSTEIN L.P. | BioXcel Therapeutics, Inc. | 1,508,768 | 5.4% | EDGAR |
| SC 13G/A | 2022-02-09 | STATE STREET CORP | BioXcel Therapeutics, Inc. | - | 4.8% | EDGAR |
| SC 13G/A | 2022-02-09 | FMR LLC | BioXcel Therapeutics, Inc. | 4,197,049 | 15.0% | EDGAR |
| SC 13G/A | 2021-07-12 | FMR LLC | BioXcel Therapeutics, Inc. | 3,114,813 | 11.0% | EDGAR |
| SC 13G/A | 2021-02-16 | BioXcel Holdings, Inc. | BioXcel Therapeutics, Inc. | 9,020,000 | 37.0% | EDGAR |
| SC 13G | 2021-02-11 | STATE STREET CORP | BioXcel Therapeutics, Inc. | - | 6.9% | EDGAR |
| SC 13G/A | 2021-02-08 | FMR LLC | BioXcel Therapeutics, Inc. | 2,001,988 | 8.2% | EDGAR |